5 research outputs found
Poupança no sistema de saúde pela regulamentação direta de preços de venda de medicamentos biotecnológicos na Colômbia
Resumen Se desarrolló un análisis retrospectivo sobre las ventas de trece biotecnológicos regulados, entre junio del 2010 y junio del 2014, en dos escenarios: valores facturados después de la regulación de precios y valores supuestos, calculados a partir del precio de venta promedio de los seis meses anteriores a la regulación, más el índice de precios al consumidor en salud. La diferencia entre ambos escenarios supone un ahorro al sistema. Los biotecnológicos analizados generaron un ahorro de USD 38 510 787. La regulación directa de precios de medicamentos biotecnológicos le ha generado ahorros significativos al sistema de salud, visto desde las ventas registradas en Audifarma. Probablemente, el ahorro económico que ha generado esta política es superior a lo estimado inicialmente por el Gobierno.Abstract We developed a retrospective analysis on the sales of thirteen biotechnological regulated medicines between June, 2010, and June, 2014, in two scenarios: amounts billed after the price and assumed value regulation, calculated based on the average sale price during the six months prior to the regulation, plus the health consumer price index. The difference between both scenarios entails a saving for the system. The biotechnological medicines analyzed generated savings for US 38,510,787. The direct regulation of biotechnological medicines has generated significant savings for the healthcare system, as seen from the sales registered by Audifarma. Probably, the economic savings generated by this policy are above the initial government estimates
Poupança no sistema de saúde pela regulamentação direta de preços de venda de medicamentos biotecnológicos na Colômbia
Resumen Se desarrolló un análisis retrospectivo sobre las ventas de trece biotecnológicos regulados, entre junio del 2010 y junio del 2014, en dos escenarios: valores facturados después de la regulación de precios y valores supuestos, calculados a partir del precio de venta promedio de los seis meses anteriores a la regulación, más el índice de precios al consumidor en salud. La diferencia entre ambos escenarios supone un ahorro al sistema. Los biotecnológicos analizados generaron un ahorro de USD 38 510 787. La regulación directa de precios de medicamentos biotecnológicos le ha generado ahorros significativos al sistema de salud, visto desde las ventas registradas en Audifarma. Probablemente, el ahorro económico que ha generado esta política es superior a lo estimado inicialmente por el Gobierno.Abstract We developed a retrospective analysis on the sales of thirteen biotechnological regulated medicines between June, 2010, and June, 2014, in two scenarios: amounts billed after the price and assumed value regulation, calculated based on the average sale price during the six months prior to the regulation, plus the health consumer price index. The difference between both scenarios entails a saving for the system. The biotechnological medicines analyzed generated savings for US 38,510,787. The direct regulation of biotechnological medicines has generated significant savings for the healthcare system, as seen from the sales registered by Audifarma. Probably, the economic savings generated by this policy are above the initial government estimates
Poupança no sistema de saúde pela regulamentação direta de preços de venda de medicamentos biotecnológicos na Colômbia
We developed a retrospective analysis on the sales of thirteen biotechnological regulated medicines between June, 2010, and June, 2014, in two scenarios: amounts billed after the price and assumed value regulation, calculated based on the average sale price during the six months prior to the regulation, plus the health consumer price index. The difference between both scenarios entails a saving for the system. The biotechnological medicines analyzed generated savings for US 38,510,787. The direct regulation of biotechnological medicines has generated significant savings for the healthcare system, as seen from the sales registered by Audifarma. Probably, the economic savings generated by this policy are above the initial government estimates.Se desarrolló un análisis retrospectivo sobre las ventas de trece biotecnológicos regulados, entre junio del 2010 y junio del 2014, en dos escenarios: valores facturados después de la regulación de precios y valores supuestos, calculados a partir del precio de venta promedio de los seis meses anteriores a la regulación, más el índice de precios al consumidor en salud. La diferencia entre ambos escenarios supone un ahorro al sistema. Los biotecnológicos analizados generaron un ahorro de USD 38 510 787. La regulación directa de precios de medicamentos biotecnológicos le ha generado ahorros significativos al sistema de salud, visto desde las ventas registradas en Audifarma. Probablemente, el ahorro económico que ha generado esta política es superior a lo estimado inicialmente por el Gobierno..Análise retrospectiva sobre as vendas de treze biotecnológicos regulados entre junho de 2010 e junho de 2014 desenvolvida em dois cenários: valores faturados após regulamentação de preços e valores supostos, calculados a partir do preço de venda médio dos seis meses prévios à regulamentação, mais o índice de preços ao consumidor em saúde. A diferença entre ambos cenários supõe poupança para o sistema. Os biotecnológicos analisados geraram poupança de USD 38 510 787. A regulamentação direta de preços de medicamentos biotecnológicos gerou poupança significativa ao sistema de saúde, visto desde as vendas registradas em Audifarma. Provavelmente, a poupança económica gerada por esta política é superior do estimado inicialmente pelo Governo
Evolution over Time of Ventilatory Management and Outcome of Patients with Neurologic Disease∗
OBJECTIVES: To describe the changes in ventilator management over time in patients with neurologic disease at ICU admission and to estimate factors associated with 28-day hospital mortality. DESIGN: Secondary analysis of three prospective, observational, multicenter studies. SETTING: Cohort studies conducted in 2004, 2010, and 2016. PATIENTS: Adult patients who received mechanical ventilation for more than 12 hours. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Among the 20,929 patients enrolled, we included 4,152 (20%) mechanically ventilated patients due to different neurologic diseases. Hemorrhagic stroke and brain trauma were the most common pathologies associated with the need for mechanical ventilation. Although volume-cycled ventilation remained the preferred ventilation mode, there was a significant (p < 0.001) increment in the use of pressure support ventilation. The proportion of patients receiving a protective lung ventilation strategy was increased over time: 47% in 2004, 63% in 2010, and 65% in 2016 (p < 0.001), as well as the duration of protective ventilation strategies: 406 days per 1,000 mechanical ventilation days in 2004, 523 days per 1,000 mechanical ventilation days in 2010, and 585 days per 1,000 mechanical ventilation days in 2016 (p < 0.001). There were no differences in the length of stay in the ICU, mortality in the ICU, and mortality in hospital from 2004 to 2016. Independent risk factors for 28-day mortality were age greater than 75 years, Simplified Acute Physiology Score II greater than 50, the occurrence of organ dysfunction within first 48 hours after brain injury, and specific neurologic diseases such as hemorrhagic stroke, ischemic stroke, and brain trauma. CONCLUSIONS: More lung-protective ventilatory strategies have been implemented over years in neurologic patients with no effect on pulmonary complications or on survival. We found several prognostic factors on mortality such as advanced age, the severity of the disease, organ dysfunctions, and the etiology of neurologic disease